Corcept (CORT) President Vieira Wandenkolk Exercises Options and Sells 58,333 Shares

What Happened
Vieira Roberto Wandenkolk, President, Oncology at Corcept Therapeutics (CORT), exercised 58,333 stock option shares at $21.63 per share (exercise cost $1,261,743) and immediately sold the 58,333 shares in multiple open‑market transactions on Sept 2, 2026 for aggregate gross proceeds of about $6,460,765. The filing also shows a Purchase Plan buy of 138 shares on Sept 1, 2026 (paid $113.38, $15,646) and an award of 138 shares (no cash cost). Separately, 102 shares were surrendered/withheld to satisfy tax obligations (value shown $11,565).

Key Details

• Primary dates: Sept 1–2, 2026 (filed Sept 3, 2026). No late filing indicated.
• Option exercise: 58,333 shares acquired at $21.63; total exercise cost $1,261,743. (Transaction code M = exercise/conversion.)
• Sales: 58,333 shares sold across multiple tranches on Sept 2; aggregate sale proceeds ≈ $6,460,765 (transaction code S = open market sale). Sale prices ranged roughly from ~$109 to ~$115 per share (weighted-average group ranges reported).
• Tax withholding/payment: 102 shares disposed to cover taxes ($11,565) (code F).
• Purchase/Award: 138 shares purchased under the employee Purchase Plan for $113.38 ($15,646) and 138 shares issued as an award at $0 (codes A).
• 10b5‑1 plan: Some sales were made pursuant to a 10b5‑1 plan adopted by the reporting person on June 17, 2026 (footnote).
• Shares owned after transaction: not specified in the excerpt of the filing.

Context

• This was effectively a cashless exercise: the number of shares exercised (58,333) equals the number of shares sold, indicating the exercised shares were immediately sold to raise proceeds and cover costs/taxes.
• Exercises followed by sales are common for executives to cover option exercise costs and tax obligations; they are routine and do not by themselves signal a change in company outlook.
• Codes: A = award/grant, M = exercise/conversion, S = sale, F = payment/withholding.